Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03503292 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics and Post-Operative Nausea and Vomiting
A Phase 4 study of Postoperative Nausea, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT03503292: Completed Phase 4 study of Postoperative Nausea, sponsored by Mayo Clinic.
NCT03503292 is a Phase 4 study of Postoperative Nausea that has completed, run by Mayo Clinic. The registered enrollment target is 92 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03503292, a Phase 4 study of Postoperative Nausea, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Primary Outcome
The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Granisetron
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 4 |
What the finished NCT03503292 record still lists
NCT03503292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Postoperative Nausea appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron is the first listed.
NCT03503292 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03503292 about?
NCT03503292 is a clinical study titled "Pharmacogenomics and Post-Operative Nausea and Vomiting". The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor an...
What is the current status of trial NCT03503292?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2018-05-02. Estimated completion is 2019-12-30.
What conditions does trial NCT03503292 study?
This clinical trial studies the following conditions: Postoperative Nausea.
What interventions are being tested in trial NCT03503292?
The interventions under investigation include: Ondansetron (DRUG), Granisetron (DRUG).
Who is sponsoring clinical trial NCT03503292?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03503292 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03503292's enrollment target sits among peer trials
92 876th of 2000 higher than 1,118 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI